Importantly, several CCR1 antagonists have entered clinical trials, including MLN3897 and CP-481,715 for rheumatoid arthritis, BX471 for multiple sclerosis, AZD-4818 for chronic obstructive pulmonary disease [233], and BAY86-5047 for endometriosis [234]. This evidence concerns the gene CCR1 and rheumatoid arthritis.